Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases
Abstract Background Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is...
Main Authors: | He-liang Wu, Zhi-ran Yang, Yan-dong Su, Ru Ma, Xue-mei Du, Ying Gao, Yan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12957-022-02811-y |
Similar Items
-
NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine
by: He-liang Wu, et al.
Published: (2022-04-01) -
Quantitative Evaluation by Digital Pathology of Immunohistochemical Expression of CK7, CK19, and EpCAM in Advanced Stages of NASH
by: Daniela Cabibi, et al.
Published: (2024-02-01) -
Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
by: Anita Sejben, et al.
Published: (2023-04-01) -
Diffuse Peritoneal Malignant Mesothelioma Presenting with Abnormal Uterine Bleeding: Case Report
by: Ivana Rizzuto, et al.
Published: (2022-03-01) -
Recurrent malignant peritoneal mesothelioma treated by a second resection: A case report
by: Takashi Miyata, et al.
Published: (2023-05-01)